SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes

被引：0
|
作者：
Irene Fernández-Ruiz
机构：
[1] Nature Reviews Cardiology,
来源：
Nature Reviews Cardiology | 2024年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular events by 20% compared with placebo in patients who are overweight or obese and with pre-existing cardiovascular disease but without diabetes mellitus, according to findings from the SELECT trial.
引用
收藏
页码：69 / 69
相关论文
共 50 条
  • [31] Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
    Ghusn, Wissam
    Fansa, Sima
    Anazco, Diego
    Tama, Elif
    Nicolalde, Bryan
    Gala, Khushboo
    De la Rosa, Alan
    Sacoto, Daniel
    Cifuentes, Lizeth
    Campos, Alejandro
    Feres, Fauzi
    Hurtado, Maria Daniela
    Acosta, Andres
    INTERNATIONAL JOURNAL OF OBESITY, 2024, 48 (05) : 662 - 667
  • [32] Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
    Wissam Ghusn
    Sima Fansa
    Diego Anazco
    Elif Tama
    Bryan Nicolalde
    Khushboo Gala
    Alan De la Rosa
    Daniel Sacoto
    Lizeth Cifuentes
    Alejandro Campos
    Fauzi Feres
    Maria Daniela Hurtado
    Andres Acosta
    International Journal of Obesity, 2024, 48 : 662 - 667
  • [33] Dietary interventions for weight loss and cardiovascular risk reduction in people of African ancestry (blacks): a systematic review
    Osei-Assibey, G.
    Boachie, C.
    PUBLIC HEALTH NUTRITION, 2012, 15 (01) : 110 - 115
  • [34] Effectiveness of Popular Weight Loss Diets on Cardiovascular Risk Reduction
    Worel, Jane Nelson
    Hayman, Laura L.
    JOURNAL OF CARDIOVASCULAR NURSING, 2015, 30 (03) : 184 - 185
  • [35] Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions
    Hakariya, Hayase
    Ohnishi, Mutsuko
    Tanimoto, Tetsuya
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3006 - 3008
  • [36] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease
    Lincoff, A. Michael
    Ryan, Donna H.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (02) : 93 - 94
  • [37] Diabetes management in older people: a focus on cardiovascular risk reduction
    McNicholas, Emily
    Abdelhafiz, Ahmed H.
    POSTGRADUATE MEDICINE, 2017, 129 (02) : 169 - 177
  • [38] Effect of a weight-loss stabilization following a weight reduction with or without meal replacement on cardiometabolic risk in overweight women. A randomized controlled trial
    Armborst, Deborah
    Metzner, Christine
    Bitterlich, Norman
    Lemperle, Martin
    Siener, Roswitha
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2019, 70 (04) : 453 - 466
  • [39] Efficacy and Safety of Semaglutide for Weight Loss in Obesity without Diabetes: A Systematic Review and Meta-Analysis
    Tan, Hanna Clementine
    Dampil, Oliver Allan
    Marquez, Maricar Mae
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2022,
  • [40] Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
    Clementine Tan, Hanna
    Allan Dampil, Oliver
    Mae Marquez, Maricar
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2022, 37 (02): : 65 - 72
12345